avelumab
EMA has validated Merck and Pfizer’s MAA for avelumab
November 1, 2016Manufacturing and Production, Sales and Marketing EMA, Merck KGaA, Pfizer, avelumab
The European Medicines Agency has validated the Marketing Authorisation Application for avelumab for the proposed indication of metastatic Merkel cell …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer
July 6, 2016Research and Development Merck, Pfizer, avelumab
Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …
Pivotal avelumab data in Merkel cell carcinoma presented at ASCO
June 6, 2016Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma
New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Merck and Pfizer kick off Phase III avelumab cancer trials
December 23, 2015Research and Development Merck, Pfizer, avelumab, ovarian cancer
Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
Merck KGaA reveals ASCO plans
May 15, 2015Sales and Marketing ASCO, Merck, Merck KGaA, Merck Serono, avelumab
Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, and like other firms it …
Merck KGaA and Pfizer alliance begins lung cancer study
April 21, 2015Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo
Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
